Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.29 – $1.34
25% from low
Exchange
OTC Link
OS
Borrow rate
12.81%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $93.9K | $67.9K | $3.9M | $964.7K | $2.0M | $2.1M | $0 |
| Cost of revenue | $1.5M | $1.5M | $2.2M | $4.0M | $1.5M | $2.1M | $3.8M | $0 |
| Gross profit | −$1.5M | −$1.4M | −$2.1M | −$150.0K | −$503.0K | −$129.0K | −$1.7M | $0 |
| Gross margin | — | -1494.5% | -3127.3% | -3.9% | -52.1% | -6.5% | -78.0% | — |
| R&D | $1.4M | $1.3M | $2.0M | $3.8M | $1.3M | $1.9M | $3.7M | −$9.5K |
| Operating income | −$3.0M | −$2.1M | −$4.6M | −$1.2M | −$1.4M | −$3.4M | −$3.9M | −$1.5M |
| EBITDA | −$3.0M | −$2.0M | −$4.5M | −$892.0K | −$1.1M | −$2.9M | −$3.5M | −$1.3M |
| Net income | −$3.0M | −$2.1M | −$4.6M | −$1.2M | −$1.4M | −$3.3M | −$3.9M | −$1.6M |
| Net margin | — | -2229.5% | -6818.8% | -30.1% | -146.0% | -167.7% | -184.7% | — |
| EPS (diluted) | -0.05 | -0.04 | -0.08 | -0.02 | -0.02 | -0.05 | -0.06 | -0.02 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.16 | $-0.16–$-0.16 | 1 |
| 2027 | $0 | $-0.04 | $-0.04–$-0.04 | 1 |
Forward consensus · source: Financial Modeling Prep
ARCH BIOPARTNERS INC ORD
No one on the platform currently holds ACHFF.
No tracked institution reports a position in ACHFF as of their last filing.
No one on the platform has traded ACHFF yet.
| $20M |
| — |
| PSYBFPsyBio Therapeutics Corp | $0.00 | +0.00% | $1275 | — |
| RLFTFMindMaze Therapeutics Holding S.A. | $0.27 | -8.57% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× sales vs its 43.2× historical median P/S.
Fair value ≈ $-0.17 · price $0.55 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.